GLP-1 & PCOS
GLP-1 Drugs for PCOS: What the Evidence Actually Shows
Semaglutide and tirzepatide are showing up in more PCOS conversations -- and for good reason. They target the hyperinsulinemia that drives androgen excess, which is the core hormonal problem in most PCOS cases. Here is what the clinical data show and what to realistically expect.
TL;DR -- PCOS is largely an insulin problem. High insulin drives the ovaries to overproduce androgens. GLP-1 agonists lower insulin, which lowers androgens, which can restore cycle regularity, reduce hirsutism, and improve metabolic markers. They are not fertility drugs and do not guarantee ovulation.
Calculate Your Dose
Most-used GLP-1s for PCOS
Women with PCOS most commonly use semaglutide or tirzepatide. Both calculators cover reconstitution and weekly dose math.
Root Cause
Why PCOS and Insulin Resistance Go Together
The dominant theory of PCOS pathophysiology centers on a self-reinforcing insulin-androgen loop:
Hyperinsulinemia drives ovarian androgen production. Insulin acts on theca cells in the ovary, stimulating excess testosterone and DHEA-S synthesis. The more insulin resistance, the more compensatory insulin the pancreas secretes, and the harder those cells are driven.
Excess androgens disrupt follicle development. High testosterone interferes with the normal follicular maturation cycle. Follicles stall mid-development, forming small cysts on the ovarian cortex. Ovulation either fails or becomes irregular.
Androgen excess drives visible PCOS symptoms. Hirsutism (facial/body hair), acne, scalp hair thinning, and irregular or absent periods are downstream of elevated androgens -- not a primary cause. Lowering androgens addresses these symptoms at the source.
Weight gain worsens insulin resistance. Adipose tissue -- especially visceral fat -- amplifies insulin resistance further and contributes to chronic low-grade inflammation that disrupts the HPO axis. Weight loss in any direction tends to improve PCOS markers.
Why this matters for GLP-1s: Most older PCOS treatments (metformin, spironolactone, birth control) manage symptoms or suppress one hormone. GLP-1 agonists work upstream -- by fixing the insulin signal -- which can improve multiple PCOS markers simultaneously.
Mechanism
How GLP-1 Agonists Help PCOS
GLP-1 receptor agonists improve PCOS through three overlapping pathways:
Lower fasting and postprandial insulin. By amplifying glucose-dependent insulin secretion and improving beta-cell function, GLP-1s reduce the chronic hyperinsulinemia that over-stimulates ovarian androgen production.
Reduce visceral adiposity. GLP-1 agonists produce 5--20% body weight loss, with a disproportionate reduction in visceral fat. Since visceral adipose tissue is a major driver of insulin resistance in PCOS, this compounds the insulin-lowering effect.
Lower circulating androgens. Clinical trials show reductions in total testosterone, free testosterone, and DHEA-S in women with PCOS on GLP-1 protocols. These reductions are partly weight-dependent and partly weight-independent (direct insulin-mediated effects on the ovary).
Downstream effects: Lower androgens frequently produce more regular menstrual cycles, reduced hirsutism progression, improved acne, and better LH/FSH ratios within 3--6 months of consistent use.
Clinical Evidence
What the Trials Show
Dedicated semaglutide trials in PCOS populations (published 2022--2025) consistently show:
Cycle regularity improves in 60--75% of subjects. Women with amenorrhea or oligomenorrhea on semaglutide 0.5--1.0mg weekly show cycle resumption or meaningful improvement in cycle frequency within 6 months, compared to 20--35% on metformin alone.
Total testosterone falls 20--35%. Multiple small RCTs (n=30--120) report significant reductions in total and free testosterone alongside reductions in HOMA-IR. The androgen reduction is proportional to, but not fully explained by, weight loss alone.
DHEA-S and LH:FSH ratios normalize. The LH:FSH ratio (typically elevated in PCOS) tends toward normal ranges on GLP-1 therapy, suggesting partial restoration of hypothalamic-pituitary signaling alongside the direct ovarian effects.
Anti-Mullerian Hormone (AMH) trends down. Elevated AMH is a PCOS marker reflecting antral follicle overload. Several trials show AMH reductions of 15--25% on semaglutide, consistent with partial normalization of follicular dynamics.
Limitation: Most PCOS-specific GLP-1 trials are small (under 200 participants) and short (6--12 months). Larger long-term RCTs are ongoing. These results are promising but not yet at the same evidence level as the weight-management trial data.
Tirzepatide vs Semaglutide
Does Tirzepatide Have an Edge for PCOS?
Tirzepatide adds GIP (glucose-dependent insulinotropic polypeptide) receptor agonism on top of GLP-1. GIP receptors are expressed in adipose tissue and skeletal muscle, producing additive improvements in insulin sensitivity beyond what GLP-1 alone achieves.
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Insulin sensitivity | Improved | Improved more |
| Average weight loss | ~15% body weight | ~20% body weight |
| PCOS trial data | Multiple small RCTs | Limited, ongoing |
| Starting dose (women) | 0.25mg/week | 2.5mg/week |
| GI side effects | Moderate | Similar |
Bottom line: For women whose PCOS is driven primarily by severe insulin resistance, tirzepatide's dual mechanism may produce greater androgen reductions per unit of weight lost. However, semaglutide has more PCOS-specific published data and a longer track record. Either is a reasonable starting point.
Dosing
Dosing Notes for Women with PCOS
Women with PCOS often see meaningful metabolic improvements at lower doses than the published weight-loss maximum doses. Slower titration also improves tolerability.
1
Semaglutide: start at 0.25mg weekly. Many women report improved cycle regularity and reduced androgen symptoms at 0.5--1.0mg weekly -- well below the 2.4mg Wegovy ceiling. There is no advantage to rushing to maximum dose.
2
Tirzepatide: start at 2.5mg weekly. Titrate to 5--10mg based on tolerance and response. Clinical PCOS benefit has been reported at 5--7.5mg in early data, though individual variation is high.
3
Titrate every 4--8 weeks, not every 4. The standard 4-week titration schedule is designed for weight loss maximization. For PCOS, slower titration reduces GI side effects significantly and still achieves the metabolic goals.
4
Give it 3--6 months before evaluating hormonal response. Weight-independent androgen effects start within weeks, but cycle normalization typically requires 3--6 months of consistent use at an effective dose. Serum testosterone and DHEA-S should be retested at 3 months minimum.
Common Stack
PCOS Supplement Stack on GLP-1
These OTC supplements are commonly combined with GLP-1 therapy in PCOS. None require a prescription and all have independent clinical evidence in PCOS populations.
Myo-inositol 2--4g/day -- the most-studied PCOS supplement. Acts as a second messenger for insulin signaling in the ovary. Meta-analyses show improvements in insulin sensitivity, testosterone, and cycle regularity independent of GLP-1. Often combined as myo:D-chiro in a 40:1 ratio. Well-tolerated, no meaningful drug interactions with GLP-1s.
Berberine 500mg 3x daily with meals -- plant alkaloid that activates AMPK, improving insulin sensitivity via a pathway distinct from GLP-1. Often described as a "natural metformin." See our berberine vs metformin comparison for a full breakdown. Some GI overlap with GLP-1 side effects -- start at 500mg 1x daily and titrate up.
Vitamin D3 2000--4000 IU/day -- vitamin D deficiency is prevalent in PCOS (estimated 67--85%) and correlates with insulin resistance severity. Supplementation at corrective doses improves HOMA-IR and has modest positive effects on cycle regularity in deficient women. Check serum 25-OH-D before dosing.
Magnesium glycinate 200--400mg nightly -- magnesium deficiency is common in insulin resistance states. Glycinate form has the least GI irritation and doubles as a sleep aid, which benefits cortisol regulation. Useful for managing GLP-1 constipation as well.
What Not to Expect
GLP-1s Are Not Fertility Drugs
This distinction matters. Cycle regularization and ovulation are different things.
Regular cycles do not mean regular ovulation. Many PCOS women on GLP-1 see cycle resumption -- periods occurring every 28--35 days -- but anovulatory cycles (bleeding without egg release) remain common. Do not assume fertility has been restored based on cycle regularity alone.
Contraception remains necessary if not trying to conceive. As cycles and ovulation become less predictable, unplanned pregnancies have been reported in women on GLP-1s who assumed they were still anovulatory. Use contraception consistently.
GLP-1s are not recommended during pregnancy. Semaglutide and tirzepatide are Category X-equivalent for pregnancy. If trying to conceive, GLP-1 therapy should be stopped and a reproductive endocrinologist consulted. The washout for semaglutide is approximately 2 months before attempting conception.
Hirsutism improvement is slow. Existing terminal hairs (coarse, dark body/facial hair) do not reverse with androgen reduction alone -- they require physical removal. GLP-1 therapy can slow new growth and reduce its coarseness over 6--12 months, but will not eliminate established hirsutism without hair removal.
Fertility and pregnancy planning: Any PCOS woman considering GLP-1 therapy who is also planning pregnancy, or who is not using reliable contraception, should discuss timing with a reproductive endocrinologist before starting.
FAQ
Common Questions
Can semaglutide help PCOS?
Yes. Semaglutide lowers fasting insulin and reduces androgen levels in women with PCOS. Clinical trials show improved menstrual cycle regularity, reductions in testosterone and DHEA-S, and significant weight loss. It addresses the primary hormonal driver -- hyperinsulinemia -- that sustains the androgen excess cycle.
Is tirzepatide better than semaglutide for PCOS?
Tirzepatide's added GIP receptor agonism produces greater improvements in insulin sensitivity than semaglutide at equivalent weight loss. For women whose PCOS is primarily driven by severe insulin resistance, tirzepatide may produce larger androgen reductions per kilogram lost. Head-to-head PCOS trial data are limited as of mid-2026, but metabolic outcome data from SURMOUNT trials favor tirzepatide for insulin resistance overall.
Will my period come back on semaglutide or tirzepatide?
Many women with PCOS do see improved cycle regularity -- often within 3 to 6 months. However, cycle resumption does not guarantee ovulation, and ovulation does not guarantee fertility. Women who are not trying to conceive should use contraception, as unexpected ovulation can occur.
What dose of semaglutide should women with PCOS start at?
Most PCOS protocols start at 0.25mg semaglutide weekly and titrate to 0.5--1.0mg. Meaningful androgen reductions have been reported at doses well below the Wegovy maximum of 2.4mg. Going slow reduces GI side effects and avoids overshooting the minimum effective dose. Tirzepatide typically starts at 2.5mg weekly for the same reason.
Should I take inositol with a GLP-1 agonist for PCOS?
Myo-inositol and D-chiro-inositol are well-studied insulin sensitizers with a strong safety record in PCOS. They work via a different mechanism from GLP-1s and are commonly combined without known interactions. A typical dose is myo:D-chiro in a 40:1 ratio, 2--4g per day. Berberine 500mg 3x daily is another OTC option with complementary effects.
Are GLP-1 agonists approved for PCOS?
As of 2026, no GLP-1 agonist has an FDA indication specifically for PCOS. Semaglutide (Wegovy) is approved for chronic weight management and tirzepatide (Zepbound) for obesity. Their use in PCOS is off-label but widely discussed in endocrinology literature and increasingly used in clinical practice for PCOS women who also meet weight-management criteria.
Not medical advice. This guide is for educational and research purposes only. GLP-1 receptor agonists are prescription medications. PCOS and fertility management require licensed medical supervision. Consult a healthcare provider before starting, adjusting, or stopping any protocol.
Compare
Ozempic vs Mounjaro
Full head-to-head breakdown
Compare
Berberine vs Metformin
OTC vs prescription for IR
Peptide Pulse Newsletter
Get the next guide before everyone else
One email a month. Dosing protocols, new peptide breakdowns, research summaries. Unsubscribe anytime.
© 2024--2026 ASCEND · Calculator · Learn Hub · About · Privacy
For research & educational use only. Not medical advice.
For research & educational use only. Not medical advice.